These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 9702468

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone.
    Segal P, Feig PU, Schernthaner G, Ratzmann KP, Rybka J, Petzinna D, Berlin C.
    Diabetes Care; 1997 May; 20(5):687-91. PubMed ID: 9135927
    [Abstract] [Full Text] [Related]

  • 3. Long-term titrated-dose alpha-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients.
    Johnston PS, Feig PU, Coniff RF, Krol A, Davidson JA, Haffner SM.
    Diabetes Care; 1998 Mar; 21(3):409-15. PubMed ID: 9540024
    [Abstract] [Full Text] [Related]

  • 4. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.
    Johnston PS, Lebovitz HE, Coniff RF, Simonson DC, Raskin P, Munera CL.
    J Clin Endocrinol Metab; 1998 May; 83(5):1515-22. PubMed ID: 9589648
    [Abstract] [Full Text] [Related]

  • 5. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition.
    Johnston PS, Feig PU, Coniff RF, Krol A, Kelley DE, Mooradian AD.
    Diabetes Care; 1998 Mar; 21(3):416-22. PubMed ID: 9540025
    [Abstract] [Full Text] [Related]

  • 6. Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.
    Drent ML, Tollefsen AT, van Heusden FH, Hoenderdos EB, Jonker JJ, van der Veen EA.
    Diabetes Nutr Metab; 2002 Jun; 15(3):152-9. PubMed ID: 12173729
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
    Johnson AB, Taylor R.
    Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.
    Chiasson JL, Naditch L, Miglitol Canadian University Investigator Group.
    Diabetes Care; 2001 Jun; 24(6):989-94. PubMed ID: 11375358
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of alpha-glucosidase inhibition on glucose profiles in insulin dependent diabetes.
    Hillman RJ, Scott M, Gray RS.
    Diabetes Res; 1989 Feb; 10(2):81-4. PubMed ID: 2663321
    [Abstract] [Full Text] [Related]

  • 15. [The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office].
    Fehmann HC.
    Fortschr Med Orig; 2001 Jul 19; 119 Suppl 2():55-61. PubMed ID: 15704357
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
    Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C.
    Cochrane Database Syst Rev; 2005 Apr 18; 2005(2):CD003639. PubMed ID: 15846673
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.